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The respiratory chain of the human malaria parasite Plasmodium
falciparum lacks a canonical protonmotive NADH:ubiquinone
oxidoreductase (Complex I), containing instead a single-subunit,
non-protonmotive NDH2, similar to that found in plant mitochon-
dria, fungi and some bacteria [1,2]. As such, the P. falciparum NDH2
(PfNDH2) presents itself as an attractive anti-malarial chemothe-
rapeutic target, and we have developed a heterologous expression
system for this enzyme in the E. coli NADH dehydrogenase
knockout strain ANN0222 (generously provided by Prof. Thorsten
Friedrich, Freiburg) to facilitate its physicochemical and enzymo-
logical characterisation [3]. PfNDH2 represents a metabolic choke
point in the respiratory chain of P. falciparum mitochondria and is
the focus of a drug discovery programme towards the development
of a novel therapy for uncomplicated malaria. Here we describe a
miniaturised assay for recombinant PfNDH2 with robust assay
performance measures that has been utilised for the high
throughput screening (HTS) of small molecule inhibitors. The
objectives of the HTS were to (i) increase the number of selective
PfNDH2 inhibitors and (ii) to expand the number of inhibitor
chemotypes. At the time of screening, only one proof of concept
molecule, 1-hydroxy-2-dodecyl-4-(1H)quinolone (HDQ), was
known to have PfNDH2 inhibitory activity (IC50=70 nM) [3,4].
This molecule was used to initiate a primary similarity-based
screen of 1000 compounds from a compound collection of 750000
compounds (curated by Biofocus-DPI). A range of chemoinfor-
matics methods and filters were applied to the hits from this initial
phase in order to perform a hit expansion screen on a further about
16000 compounds. The chemoinformatic strategy allowed us to
cover about 16% diversity whilst screening just about 2% of the
compound collection. The HTS resulted in a hit rate of 0.29% and
150 compounds were progressed for potency against PfNDH2. Of
these compounds, 50 were considered active with IC50s ranging
from 100 nM to 40 µM. Currently, seven distinct chemotypes are
being progressed from hit to lead using traditional synthetic
medicinal chemistry strategies.
References
[1] Biagini GA et al. (2006) Antimicrob. Agents Chemother. 50: 1841-1851.
[2] Fisher N et al. (2007) Trends. Parasitol. 23: 305-310.
[3] Fisher N. et al. (2009) Meth. Enzymol. 456: 303-320.
[4] Saleh A et al. (2007) Antimicrob. Agents Chemother. 51: 1217-1222.
doi:10.1016/j.bbabio.2010.04.241
9P.4 Mitochondrial function and idebenone: A good therapy for
Leber's hereditary optic neuropathy?
Valentina Giorgio, Paolo Bernardi, Valeria Petronilli
Consiglio Nazionale delle Ricerche, Institute of Neuroscience at the
Department of Biomedical Sciences, University of Padova, Padova, Italy
E-mail: vgiorgio@bio.unipd.it
Idebenone [2,3-dimethoxy-5-methyl-6(10-hydroxidecyl)-1,4-
benzoquinone] is a synthetic analogue of coenzyme Q10 (CoQ10),
an essential constituent of the mitochondrial electron transport chain
and a powerful antioxidant. Idebenone is also a good electron carrier
in the mitochondrial respiratory chain. Quinones (including idebe-
none) have also been shown to affect the mitochondrial permeability
transition (PT) pore (PTP) a high-conductance inner membrane chan-
nel modulated by the proton electrochemical gradient and by many
signaling molecules. PTP links oxidative stress to cell death and seems
to be involved in Leber's hereditary optic neuropathy (LHON) and
other pathologies of neurological interest. Given these complex ef-
fects of idebenone on cellular bioenergetics we have investigated its
effects on bioenergetics and PTP modulation in intact cells. Our
preliminary results indicate that: (i) idebenone modulates the PTP in
situ through an interaction with NEM-sensitive thiols, with an effect
that can be inhibited by Cyclosporin A (CsA); (ii) DTT prevents the
PTP-inducing effects of idebenone, and promotes electron transfer
from idebenone to complex III of the respiratory chain bypassing the
lack of complex I activity; (iii) in the presence of DTT, idebenone
considerably increases antimycin A-sensitive respiration both in nor-
mal and in RJ206 cells (harboring the 3460/ND1 LHON mutation)
and XTC.UC1 thyroid oncocytoma cells (bearing a disruptive frame-
shift mutation in the MT-ND1 gene which impairs complex I
assembly). The key question of whether idebenone-supported
respiration is used for ATP synthesis is being addressed.
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Treatment with the ω-3 polyunsaturated fatty acids (PUFAs)
docosahexanoic acid (DHA) and eicosapentanoic acid (EPA) exerts
cardioprotective effects in patients, and suppresses Ca2+-induced
opening of the mitochondrial permeability transition pore (MPTP) in
vitro. These effects are associated with increased DHA and EPA and
lower arachidonic acid (ARA) in cardiac phospholipids. ARA is
implicated in inflammation and induction of MPTP opening. While
clinical studies suggest the triglyceride lowering effects of DHA and
EPA are equivalent, there is growing evidence that DHA may be
superior at remodeling mitochondrial phospholipids and preventing
MPTP. Therefore we compared the effects of dietary supplementation
with the ω-3 PUFAs DHA and EPA on cardiac mitochondrial phos-
pholipid fatty acid composition and Ca2+-inducedMPTP opening. Rats
were fed either a control (CTRL) low-fat chow, or a similar diet
supplementedwith either DHA or EPA only at 2.5% of energy intake for
8 weeks. These doses of DHA and EPA are comparable to about 5 g/day
in humans. Cardiacmitochondriawere isolated and analyzed for Ca2+-
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induced MPT, respiration, and phospholipid fatty acyl composition.
Both DHA and EPA enriched diets lowered circulating free fatty acids
and triglycerides byapproximately 40% (p<0.05, DHAvs CTRL and EPA
vs CTRL, NS, DHAvs EPA). DHA supplementation increasedDHAby 63%
(p<0.05 vs control) and decreased ARA by 61% (p<0.05 vs control) in
mitochondrial phospholipids, and significantly delayedMPTP opening
(57% more calcium necessary to induce MPTP vs CTRL, p<0.05). EPA
supplementation did not affect DHA, only modestly lowered ARA
(−33% vs CTRL, p<0.05), and had no effect of MPTP opening. State 3
respiration with a variety of substrates was unaffected by dietary
treatment, however DHA decreased state 4 respiration by 30% and the
increased RCR by 70% with pyruvate+malate as the substrate, both in
the absence and presence of oligomycin (p<0.05); treatmentwith EPA
had no effect. The P:O ratiowas not different among groupswith any of
the substrates. In summary, DHA supplementation favorably altered
mitochondrial phospholipid composition and delayed MPT in cardiac
mitochondria, while EPA had no effect. These effects may contribute to
the protection against heart disease with ω-3 PUFA supplementation,
and suggest that supplementationwithDHA should be superior to EPA.
doi:10.1016/j.bbabio.2010.04.243
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Nitroalkenes are electrophilic molecules which can cause post-
translational modifications of proteins and modulate their functional
activity. Previously we demonstrated endogenous formation of ni-
trated linoleate (LNO2) in mitochondria isolated from perfused heart
after ischemic preconditioning. In addition, synthetic LNO2 protected
isolated cardiomyocytes against simulated ischemia/reperfusion
injury. Biotin-tagged LNO2 replicated this cardioprotective effect,
and caused reversible modification of mitochondrial proteins. Thus,
we hypothesized that mitochondrial targets of LNO2 might play an
important role in cardioprotection. Previously we demonstrated that
LNO2 induced mitochondrial H+ leak viamodification of ANT. Further
studies revealed that LNO2 (1 µM) opened mitochondrial KATP
channels in a 5-HD and glybenclamide sensitive manner. Although
the molecular identity of the mKATP channel has not been fully
elucidated, we previously showed that complex (Cx) II might be
involved in regulation of mKATP channel activity. We found that LNO2
physically interacted with the 70 kDa subunit of Cx II and inhibited
its enzymatic activity. Notably, the cardioprotective effects of mild H+
leak, opening of mKATP channels and reversible inhibition of the respi-
ratory chain are well documented. Thus, our findings characterize
LNO2 as a pleotropic molecule which might recruit several protective
mitochondrial pathways to elicit cardioprotection.
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Nowadays, Doxorubicin (DOX) is probably one of the most effec-
tive anticancer drugs available in the clinic. However, the treatment
is usually followed by a cumulative and persistent cardiotoxicity.
Mitochondria have a critical role in DOX-mediated toxicity however
there are still doubts whereas mitochondrial toxicity is specific to the
heart. Therefore, the present work characterizes two differentmodels of
toxicity (acute vs. sub-chronic), regarding mitochondrial physiology
from three different tissues (heart, liver and kidney) from treated rats.
Wistar rats were sub-chronically (7 wks, 2 mg/kg) or acutely (20 mg/
kg) treated with DOX and allowed to rest oneweek or 24 h after the last
injection, respectively. Sub-chronically-treated animals showed a de-
crease in body mass gain during treatment while no changes were
observed in acute model. Plasma profile from both models was altered
but the sub-chronic treatment presented the most dramatic changes.
Histological analysis revealed the presence of lipid droplets in liver slices
from acutely treated rats. Regarding mitochondrial bioenergetics,
differences between saline and DOX-treated rats were observed: in the
acute model, differences included state 3 respiration in the liver and
kidneyand theADP/O in theheart. In the sub-chronicmodel, differences
regarding state 3 respiration in the heart and kidney was observed. We
also determined that cardiac mitochondria from sub-chronic-treated
animals presented a lower calcium loading capacity, which was not
observed in the other tissues. However, gene expression analyses
showed no alterations in the chronic model but interestingly, decreased
mRNA levels for the ANT, VDAC and increased CyP-D mRNA were
detected in the acute model. Aconitase activity, a sensitive marker of
oxidative stress, was decreased in the kidney (acute model) and in the
heart (sub-chronic model). In conclusion, data confirm that mitochon-
drial alterations result from DOX treatment, being more severe in the
heart and are very dependent on the treatment protocol. It remains to be
determined if mitochondrial alterations in organs such as liver and
kidneys are a specific and direct effect of DOX onmitochondria or if they
result of secondary effects of DOX on other targets.
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36938/2007 to GP, PTDC/SAU-OSM/64084/2006 and PTDC/SAU-
OSM/104731/2008 to PO).
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Glycine, inhibitory neurotransmitter, has been found to be effective
against neuronal cell death in in vivo and in vitro models of ischemic
stroke. We have shown that glycine prevented respiratory index
depletion of mitochondria in the homogenate of the cerebral cortex after
24 h common carotid artery occlusion in rats, along with preventing the
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